The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
15-Dec-19
$45.4 billion
Target:
Nutrition & Biosciences Division of DuPont de Nemours, Inc.
Acquiror:
International Flavors and Fragrances, Inc.
Advising IFF, a global leader in flavors and fragrances, on its merger with DuPont’s Nutrition & Biosciences Division, creating a clear global leader in the specialty ingredients sector
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
27-Oct-22
$950 million
Target:
Minnesota Rubber and Plastics
Acquiror:
Trelleborg
Facilitated the sale of KKR’s portfolio company Minnesota Rubber and Plastics, a leading provider of materials science-based elastomer and thermoplastic solutions, to Trelleborg
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
09-Feb-10
$672 million
Target:
SAS Group
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to a refinancing including a conditional capital injection in SAS, the leading airline group in Northern Europe
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
19-Oct-20
$546 million
Target:
Learning Materials for the K-12 Segment in Spain
Acquiror:
Sanoma Oyj
Advising Sanoma Oyj (HEL: SAA1V), a European learning and media company listed on Nasdaq Helsinki, on the acquisition of Santillana Spain, a leading Spanish provider of K-12 learning materials, from Promotora de Informaciones S.A. (Grupo Prisa, BME: PRS)
03-Oct-06
$445 million
Target:
Tele2 AB’s fixed telephony and broadband business in France
Acquiror:
SFR S.A.
Advised SFR S.A., the second largest mobile telecoms operator in France on the acquisition of the French fixed telephony and broadband business of Tele2 AB
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
04-Aug-06
$290 million
Target:
Republic Companies Group, Inc.
Acquiror:
Delek Capital Ltd.
Advised Republic Companies Group, Inc., a regional provider of personal and commercial property and casualty insurance products
01-Jun-21
$280 million
Target:
White Drive Motors & Steering business unit of Danfoss A/S
Acquiror:
Interpump S.p.A.
Advising Danfoss, a global leader in power solutions, heating, cooling and drives, on the carve-out sale of White Drive Motors & Steering, a global producer of orbital motors and hydraulic steering units for mobile applications, to Interpump
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
26-Feb-18
$224 million
Target:
Crem International
Acquiror:
Welbilt
Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines
13-Jan-05
$153 million
Target:
Deutz AG
Acquiror:
Wärtsilä Oyj
Advised Marine Service business Deutz on the sale of its marine service business for medium and large size engines to Wärtsilä
11-Jan-21
~$150 million
Target:
Nordic Water
Acquiror:
Sulzer AG
Advising Alder, a Swedish sustainability-focused private equity firm, on the divestment of Nordic Water, a supplier of products for the global water and wastewater treatment market, to Sulzer AG
21-Jan-19
$100 million
Target:
UQM Technologies, Inc.
Acquiror:
Danfoss A/S
Advised Danfoss, a global leader in power solutions, heating, cooling and drives, on its acquisition of UQM Technologies
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
17-Dec-19
~$35 million
Target:
Sye business area of Net Insight AB
Acquiror:
Amazon.com, Inc.
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
22-Sep-20
$NA
Target:
VX Fiber
Acquiror:
AMP Capital
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
21-Aug-07
$NA
Target:
Schenck Process Holding GmbH
Acquiror:
Industri Kapital Limited
Advised HgCapital on the sale of Schenck Process, one of the global market leading providers of industrial weighing, feeding, screening and automation equipment and solutions